Cointime

Biocon Biologics

company

About

Biocon is a fully integrated pure play biosimilars organization, globally engaged in developing high quality affordable biosimilars.

Highlights

Total Funding Amount
₹24.41B
Funding Rounds
4
Investors
4
Acquisition
1
Employee Profiles
2

Details

Last Funding Type
Private Equity（PE）
Last Funding Money Raised
₹2.25B
Industries
Biotechnology
Founded date
Nov 29, 1978
Number Of Employee
5001 - 10000
Operating Status
Active
Legal Name
Biocon Biologics India Ltd.

Biocon Biologics is a fully-integrated pure-play biosimilars organization globally engaged in developing high-quality, affordable biosimilars aimed at expanding patient access to cutting-edge therapies. It develops and commercializes a differentiated portfolio of novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as, generic formulations in the U.S. and Europe.

The company is driven by a belief that the pharmaceutical industry has a humanitarian responsibility to provide essential drugs to patients who are in need and to do so with the power of innovation.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
₹24.41B
Biocon Biologics has raised a total of ₹24.41B in funding over 2 rounds. Their latest funding was raised on Jan 7, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 7, 2021 Series Unknown ₹5.55B 1 ADQ — Detail
Nov 9, 2020 Private Equity（PE） ₹11.25B 1 Goldman Sachs — Detail
Jul 31, 2020 Private Equity（PE） ₹2.25B 1 Tata Capital — Detail
Jan 6, 2020 Private Equity（PE） ₹5.36B 1 True North — Detail

Investors

Number of Lead Investors
Number of Investors
4
4
Biocon Biologics is funded by 4 investors. ADQ and Goldman Sachs are the most recent investors.
Investor Name Lead Investor Funding Round
ADQ Yes Series Unknown
Goldman Sachs Yes Private Equity（PE）
Tata Capital Yes Private Equity（PE）
True North Yes Private Equity（PE）

Employee Profiles

Number of Employee Profiles
2
Biocon Biologics has 2 current employee profiles, including Executive Kiran Mazumdar-Shaw
Shreehas Tambe
Executive

Acquisition

Biocon Biologics has acquired 1 organizations. Their most recent acquisition was Viatris Biosimilars on Feb 28, 2021. They acquired Viatris Biosimilars for $3.34B.

Date Company Name
Industry Acquisition Type Price
Feb 28, 2021 Viatris Biosimilars
Biotechnology acquisition $ 3.34B Detail
Cointime
İçerikler
Şirket.